Teva Pharmaceutical Industries Limited (TEVA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 7.82 |
| Open | 7.86 |
| Bid | 8.11 x 21500 |
| Ask | 8.12 x 36900 |
| Day's Range | 7.85 - 8.24 |
| 52 Week Range | 6.78 - 11.34 |
| Volume | |
| Avg. Volume | 13,401,522 |
| Market Cap | 8.901B |
| Beta (5Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.63 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 27, 2017 |
| 1y Target Est | 10.07 |
- Motley Fool
Why Teva Stock Shot More Than 3% Higher Today
Teva Pharmaceutical Industries (NYSE: TEVA) stock closed the trading week in style, rising by over 3% on a bleak and bearish day for the wider market. Teva Pharmaceuticals, the company's key subsidiary, has reached an agreement with the southern state's attorney general to settle accusations of price-fixing. Under the terms of the arrangement, Teva is to pay just under $3.35 million; in return, once the funds are handed over Georgia will dismiss all claims against the company in the case.
- Business Wire
Teva Reaches Agreement With Georgia to Settle the State’s Price Fixing Claims
TEL AVIV, Israel & PARSIPPANY, N.J., September 30, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached an agreement with the Attorney General (AG) of Georgia to settle the state’s price-fixing claims against Teva. Teva will pay the state $3.346 million as part of the settlement, and the state will dismiss all of its claims against Teva and its affiliates once payment has been made.
- Benzinga
European Drug Makers Say Higher Energy Costs Eating Margins: Report
Europe's drug makers have warned about stopping manufacturing some cheap generic medicines amid surging electricity costs. The generic drug industry lobby group, Medicines for Europe, representing Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Novartis AG's (NYSE: NVS) Sandoz unit, and Fresenius SE's (OTC: FSNUY) Kabi business, sent a letter to European states' energy and health ministers, asking for measures to relieve the cost burden. According to Medicines for Europe, Generic associations p
